Figure 3

D₁DR expression on peripheral B cells from female RA patients correlates with clinical parameters. Differential expression of D₁DR on CD19⁺ B cells from RA patients was correlated with available patient information at day of blood withdrawal. (a) comparison of D₁DR level on CD19⁺ B cells from HC (female n = 24, male n = 16) as well as naïve RA (female n = 5, male n = 4) and treated RA (female n = 20, male n = 11) patients (b–d) D₁DR level on CD19⁺ B cells from RA patients was analyzed regarding disease duration (b, female n = 27, male n = 14), FFbH (c, female n = 27, male n = 7) and DAS28 score (d, female n = 27, male n = 6). (e, f) Quantification of D₁DR expression on CD19⁺ B cells from HC (female n = 23, male n = 14) and RA patients categorized into rheumatoid factor (RF) positive and negative (e, female n = 14 and 13, male n = 4 and 9 respectively)) or anti-citrullinated protein antibodies (ACPA) positive and negative (f, female n = 16 and 10, male n = 4 and 6 respectively). Simple linear regression with Pearson correlation analysis was used to analyze D₁DR expression in relation to clinical parameters; Brown-Forsythe and Welch ANOVA tests with Dunnett T3 multiple comparison test were used to compare D₁DR expression between groups; *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001.